Výsledky vyhledávání - "Thomenius MJ"

Akademický článek

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies.

Autor: Lampe JW; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Alford JS; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Boriak-Sjodin PA; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Brach D; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Cosmopoulos K; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Duncan KW; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Eckley ST; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Foley MA; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Harvey DM; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Motwani V; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Munchhof MJ; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Raimondi A; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Riera TV; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Tang C; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Thomenius MJ; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Totman J; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States., Farrow NA; Epizyme Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2021 Aug 24; Vol. 12 (10), pp. 1539-1545. Date of Electronic Publication: 2021 Aug 24 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

Autor: Thomenius MJ; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Totman J; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Harvey D; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Mitchell LH; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Riera TV; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Cosmopoulos K; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Grassian AR; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Klaus C; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Foley M; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Admirand EA; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Jahic H; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Majer C; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Wigle T; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Jacques SL; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Gureasko J; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Brach D; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Lingaraj T; Epizyme, Inc., Cambridge, Massachusetts, United States of America., West K; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Smith S; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Rioux N; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Waters NJ; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Tang C; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Raimondi A; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Munchhof M; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Mills JE; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Ribich S; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Porter Scott M; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Kuntz KW; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Janzen WP; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Moyer M; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Smith JJ; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Chesworth R; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Copeland RA; Epizyme, Inc., Cambridge, Massachusetts, United States of America., Boriack-Sjodin PA; Epizyme, Inc., Cambridge, Massachusetts, United States of America.

Publikováno v: PloS one [PLoS One] 2018 Jun 01; Vol. 13 (6), pp. e0197372. Date of Electronic Publication: 2018 Jun 01 (Print Publication: 2018).

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.

Autor: Brach D; Epizyme Inc., Cambridge, Massachusetts., Johnston-Blackwell D; Epizyme Inc., Cambridge, Massachusetts., Drew A; Epizyme Inc., Cambridge, Massachusetts., Lingaraj T; Epizyme Inc., Cambridge, Massachusetts., Motwani V; Epizyme Inc., Cambridge, Massachusetts., Warholic NM; Epizyme Inc., Cambridge, Massachusetts., Feldman I; Epizyme Inc., Cambridge, Massachusetts., Plescia C; Epizyme Inc., Cambridge, Massachusetts., Smith JJ; Epizyme Inc., Cambridge, Massachusetts., Copeland RA; Epizyme Inc., Cambridge, Massachusetts., Keilhack H; Epizyme Inc., Cambridge, Massachusetts., Chan-Penebre E; Epizyme Inc., Cambridge, Massachusetts., Knutson SK; Epizyme Inc., Cambridge, Massachusetts., Ribich SA; Epizyme Inc., Cambridge, Massachusetts., Raimondi A; Epizyme Inc., Cambridge, Massachusetts. araimondi@epizyme.com mthomenius@epizyme.com., Thomenius MJ; Epizyme Inc., Cambridge, Massachusetts. araimondi@epizyme.com mthomenius@epizyme.com.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2017 Nov; Vol. 16 (11), pp. 2586-2597. Date of Electronic Publication: 2017 Aug 23.

Zobrazit plný text záznamu

Akademický článek

The deubiquitinating enzyme DUBAI stabilizes DIAP1 to suppress Drosophila apoptosis.

Autor: Yang CS; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Sinenko SA; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Thomenius MJ; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Robeson AC; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Freel CD; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Horn SR; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA., Kornbluth S; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.

Publikováno v: Cell death and differentiation [Cell Death Differ] 2014 Apr; Vol. 21 (4), pp. 604-11. Date of Electronic Publication: 2013 Dec 20.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání